Related Experiment Videos
Malignant melanoma: cost and reimbursement issues
1Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
Seminars in Oncology
|February 1, 1989
Summary
Metastatic melanoma has a poor response to standard treatments. Investigational therapies show promise but face funding challenges, potentially hindering access to advanced cancer care.
Area of Science:
- Oncology
- Pharmacology
Background:
- Malignant melanoma that has metastasized beyond the epidermis demonstrates limited efficacy with conventional treatments.
- Current research focuses on novel therapeutic strategies for advanced melanoma.
Purpose of the Study:
- To highlight the challenges in accessing investigational drug therapies for metastatic melanoma.
- To discuss the financial implications of clinical trial participation and reimbursement.
Main Methods:
- Review of current investigational drug programs for malignant melanoma.
- Analysis of financial barriers and payer reluctance in clinical trial reimbursement.
Main Results:
- Biologic therapies like alpha interferon and interleukin-2 show promise but incur high costs.
- Increasing reluctance from government and third-party payers to cover clinical trial expenses.
- Potential for reduced access to cutting-edge treatments if financial support is not maintained.
Conclusions:
- Continued financial support is crucial for the advancement and accessibility of state-of-the-art melanoma treatments.
- Without adequate reimbursement, promising investigational therapies may stall, leaving patients with less effective conventional options.